"It's a big trial, and we were looking for a very targeted group of patients. It took a lot of education at the sites to make sure they understood those parameters and to make sure they were tested. But there wasn't anything particularly challenging, other than the sheer competition for oncology patients, in general."
Mark Schwartz, president and CEO, Galena Biopharma Inc., saying the company is putting into motion an extensive "operational review" of the data from the phase III PRESENT trial of cancer vaccine Neuvax (nelipepimut-S) after the independent data monitoring committee made the highly unusual suggestion to investigate whether "there has been a systematic reversal in the study drug treatments in the two arms" that may have skewed interim findings

"This is one of the biggest preclinical-stage antibody license deals, and we have a few dozen of these [assets], so that shows you the potential of what we have."
Henry Ji, president and CEO of Sorrento Therapeutics Inc., on what he called a "validating deal" for its immuno-oncology platform with Les Laboratoires Servier SAS for its fully human anti-PD-1 monoclonal antibody, STI-A1110

"This is a historic moment, the first time in decades that Congress has passed comprehensive addiction legislation, and the first time Congress has ever supported long-term addiction recovery. This is also the first time that we've treated addiction like the disease that it is, which will help put an end to the stigma that has surrounded addiction for too long."
Sen. Rob Portman (R-Ohio), one of four authors of the original bipartisan Senate bill, commenting on the U.S. Senate overwhelmingly passing the final version of the Comprehensive Addiction and Recovery Act (CARA) by a vote of 92-2, sending it to the president for his signature

"Regenerative medicine is much like personalized medicine was 10 years ago, but maybe with more potential for even more rapid expansion."
Christopher-Paul Milne, research associate professor and director of research at the Tufts Center for the Study of Drug Development, discussing his analysis on the global regenerative medicine market